GMAB
Genmab A/S Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website genmab.com
- Employees(FY) 2132
- ISIN US3723032062
Performance
+4.01%
1W
-3.23%
1M
+2.97%
3M
-2.44%
6M
-9.55%
YTD
-28.66%
1Y
Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Investment Analysis Report: GMAB
Overview
In this investment analysis report, we will delve into a comprehensive evaluation of GMAB, a company operating in the Health Technology sector within the Pharmaceuticals: Major industry. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operatin...
Technical Analysis of GMAB 2024-05-03
Overview:
In analyzing the technical indicators for GMAB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-07 14:27
- 2024-05-07 02:27
- 2024-05-06 10:01
Transactions in Connection with Share Buy-back Program(GlobeNewswire)
- 2024-05-05 22:01
Transactions in Connection with Share Buy-back Program(Globenewswire)
- 2024-05-04 00:15
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover(Morningstar Research)
- 2024-05-03 00:38
Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript(Insidermonkey)
- 2024-05-02 11:01
- 2024-05-02 04:52
- 2024-04-29 18:40
- 2024-04-29 18:40
- 2024-04-29 06:40
- 2024-04-29 06:40
- 2024-04-29 04:24
- 2024-04-28 16:24
- 2024-04-22 03:30
- 2024-04-21 15:30
- 2024-04-16 06:24
- 2024-04-15 18:24
- 2024-04-15 04:07
- 2024-04-14 16:07
- 2024-04-08 05:44
Transactions in Connection with Share Buy-back Program(GlobeNewswire)
- 2024-04-07 17:44
Transactions in Connection with Share Buy-back Program(Globenewswire)
- 2024-04-03 16:02
Genmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion Takeover(Investor's Business Daily)
- 2024-04-03 13:05
Stocks to Watch Wednesday: Disney, Intel, Tesla, Trump Media(The Wall Street Journal)
- 2024-04-03 07:28
- 2024-04-03 04:48
Genmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBio(The Wall Street Journal)
- 2024-04-03 01:35
- 2024-04-02 22:06
- 2024-04-02 20:48
- 2024-04-02 13:35
Page 1 of 7
previousnext